Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results

Delivered record-high revenues, Adjusted EBITDA 1 , Adjusted EBITDA per shar e 1 since inception Generated record high cash flow from operations since inception Provides 2026 revenues guidance of $490 million to $510 million and adjusted EBITDA 1 of approximately 15%